Objectives: To test CIDP patients for IgM positivity towards NF186, except sample 23 (towards NF155).
Patients:
| NUMBER | CODE |
|---|---|
| 1 | 18-523 |
| 2 | 18-524 |
| 3 | 18-525 |
| 4 | 18-526 |
| 5 | 18-527 |
| 6 | 18-528 |
| 7 | 18-529 |
| 8 | 18-530 |
| 9 | 18-531 |
| 10 | 18-533 |
| 11 | 18-534 |
| 12 | 18-535 |
| 13 | 18-536 |
| 14 | 18-537 |
| 15 | 18-538 |
| 16 | 18-539 |
| 17 | 18-540 |
| 18 | 18-541 |
| 19 | 18-542 |
| 20 | 18-543 |
| 21 | 18-544 |
| 22 | 18-545 |
| 23 | LAC (NF155) |
| 24 | CTRL - |
NF186 ICC:
- HEKs 293 Cells Transfection: 2018.01.16
- Blocking solution: 5% goat serum in PBS.
- Patient’s sera diluted 1/10 for IgM with 5% goat serum in PBS.
- Primary antibody: AF3235 diluted 1/1000.
- Secondary antibodies: GAH 594 IgM (1/1000) + GAC 488 (1/1000).
- Vectashield mounting medium
NF155 ICC (sample 23):
- HEKs 293 Cells Transfection: 2018.01.16
- Blocking solution: 5% goat serum in PBS.
- Patient’s sera diluted 1/100 for IgG with 5% goat serum in PBS.
- Primary antibody: AF3235 diluted 1/1000.
- Secondary antibodies: GAH 594 IgG (1/1000) + GAC 488 (1/1000).
- Vectashield mounting medium
Results: Sample 10 (sera 18-533) is positive for IgM towards NF186. Sample 23 (LAC, control +) is positive for IgG towards NF155. The other samples were negative.
